|

LBL-007 Injection Clinical Trials

1 actively recruiting trial

Also known as: LBL-007

Pipeline

Phase 1/2: 1

Top Sponsors

  • Nanjing Leads Biolabs Co.,Ltd1

Indications

  • Malignant Tumors1
  • Cancer1

Other1 trial

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.